The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The transaction is expected to close in the first quarter of 2022
Hitz shall assume new role from January 17th, 2022
The brand is now available pan-India through their distribution partner
EMBER500RNA Prestain Loading Dye allows single-step denaturing, loading, and bright RNA staining on regular agarose gels
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
Subscribe To Our Newsletter & Stay Updated
